SDGR:NASDAQSchrodinger, Inc. Analysis

Schrödinger, Inc. is trading at $14.15, comfortably above its 20‑day ($13.75) and 50‑day ($12.77) simple moving averages but still below the 200‑day average ($15.93), indicating a short‑term bullish bias within a longer‑term neutral framework. RSI sits at 53.7, suggesting neither overbought nor oversold conditions, while the MACD histogram is slightly negative and the signal line is flagged as bearish, hinting at modest downside pressure. Volume is on an increasing trend, yet the stock exhibits a very high 30‑day volatility of over 60% and a beta of ~1.9, underscoring pronounced price swings. Fundamentals are weak: the company reports a negative PE, operating margin of –83%, and a trailing EPS of –$1.40, with cash flow deficits and a debt‑to‑equity ratio above 30%. However, the balance sheet remains solid with cash ($398M) far exceeding debt ($107M), and the price‑to‑book of 3.36 is modest relative to the target mean price of $20.88, implying a potential upside of roughly 45% per analyst consensus. Recent news notes an 11% share price surge but also a 28% YTD decline and a 45% loss over the past year, reflecting mixed market sentiment. The Fear & Greed Index at “Extreme Greed” suggests speculative enthusiasm despite the underlying earnings challenges.
Given the high volatility, speculative upside, and a strategic partnership with Novartis, the stock sits at the intersection of growth opportunity and significant risk. The lack of dividend, negative cash flow, and ongoing regulatory hurdles for its drug‑discovery pipeline temper enthusiasm, while the strong cash position provides a runway for continued R&D. Investors should weigh the near‑term technical weakness against the longer‑term upside narrative driven by the company’s computational platform and analyst price targets.